Leap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation
Leap Therapeutics, Inc. (LPTX) reported a net loss of $9.5 million for Q2 2021, up from $6.5 million in 2020. License revenues remained stable at $0.4 million. Research and development expenses increased to $7.2 million, largely due to higher payroll and clinical trial costs. General and administrative expenses rose to $2.8 million. Cash reserves stood at $35.7 million as of June 30, 2021. The company completed enrollment in the DisTinGuish study for DKN-01 and plans to present initial data at the ESMO Congress in September 2021.
- Completion of enrollment in the DisTinGuish study for DKN-01.
- Upcoming presentation of initial data at ESMO Congress 2021.
- Net loss increased to $9.5 million from $6.5 million year-over-year.
- R&D expenses rose by $1.8 million primarily due to increased headcount and clinical trial costs.
CAMBRIDGE, Mass., Aug. 13, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided upcoming company milestones.
"In the first half of the year, we made significant clinical progress in the DisTinGuish study of DKN-01 in combination with BeiGene's tislelizumab, as we completed enrollment in the first-line patient cohort," said Douglas E. Onsi, President and Chief Executive Officer of Leap. "We look forward to presenting initial data from the study in September, which we believe will show the important potential role DKN-01 can play for first-line gastric cancer patients, particularly those whose tumors express high levels of DKK1 where a great unmet medical need remains unaddressed."
Key DKN-01 2021 Clinical Milestones
DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways, which play an important role in tumor cell signaling and in mediating an immuno-suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells.
Leap made substantial progress with the clinical development of DKN-01 during the first half of 2021 and has an important clinical milestone ahead this quarter:
Completion of Enrollment in First-Line Cohort in the DisTinGuish Study of DKN-01 plus Tislelizumab and Chemotherapy in Gastric Cancer. The Company announced the completion of enrollment for the first-line patient cohort in the DisTinGuish study (NCT04363801), a Phase 2a, open-label, clinical trial evaluating DKN-01 in combination with tislelizumab, BeiGene Ltd.'s (BeiGene) anti-PD-1 antibody, with or without chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ). The study, which is being conducted in two parts in the United States and the Republic of Korea, enrolled 25 patients with first-line G/GEJ cancer and is expected to enroll up to 48 patients with second-line G/GEJ cancer whose tumors express high levels of DKK1. Leap is conducting this study as part of an exclusive option and license agreement with BeiGene for the development of DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
Initial Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy to be Presented at the European Society for Medical Oncology (ESMO) Congress 2021. The Company will be presenting initial data from the cohort of 25 first-line G/GEJ cancer patients treated with DKN-01 in combination with tiselizumab and chemotherapy at the ESMO Congress 2021, being held virtually on September 16-21, 2021. Leap plans to host a conference call on Friday, September 17, 2021 to further discuss the data.
Selected Second Quarter 2021 Financial Results
Net loss was
License revenues were
Research and development expenses were
General and administrative expenses were
Cash and cash equivalents totaled
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.
RNAscope® is a registered trademark of Advanced Cell Diagnostics, Inc., Newark, CA, USA.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include Leap's expectations with respect to the development and advancement of DKN-01, including the initiation, timing and design of future studies, enrollment in future studies, potential for the receipt of future option exercise, milestone, or royalty payments from BeiGene, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and other studies may be delayed, adversely affected, or impacted by COVID-19 related issues; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially will be included in Leap Therapeutics' periodic filings with the SEC, including Leap's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the SEC on March 12, 2021 and as may be updated by Leap's Quarterly Reports on Form 10-Q and the other reports Leap files from time to time with the SEC. Any forward-looking statement contained in this release speaks only as of its date. Leap undertakes no obligation to update any forward-looking statement contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
Heather Savelle
Investor Relations
Argot Partners
212-600-1902
heather@argotpartners.com
Leap Therapeutics, Inc. | |||||||||||||||||||
Condensed Consolidated Statements of Operations | |||||||||||||||||||
(in thousands, except share and per share amounts) | |||||||||||||||||||
(Unaudited) | (Unaudited) | ||||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||
License revenue | $ | 375 | $ | 375 | $ | 750 | $ | 750 | |||||||||||
Operating expenses: | |||||||||||||||||||
Research and development | 7,206 | 5,350 | 14,013 | 9,953 | |||||||||||||||
General and administrative | 2,795 | 2,521 | 5,535 | 4,674 | |||||||||||||||
Total operating expenses | 10,001 | 7,871 | 19,548 | 14,627 | |||||||||||||||
Loss from operations | (9,626) | (7,496) | (18,798) | (13,877) | |||||||||||||||
Interest income | 1 | 20 | 3 | 88 | |||||||||||||||
Interest expense | (16) | (13) | (30) | (25) | |||||||||||||||
Australian research and development incentives | 244 | 30 | 315 | 115 | |||||||||||||||
Foreign currency gain (loss) | (129) | 943 | (150) | (48) | |||||||||||||||
Net loss | (9,526) | (6,516) | (18,660) | (13,747) | |||||||||||||||
Dividend attributable to down round feature of warrants | - | - | - | (303) | |||||||||||||||
Dividend attributable to Series A & B convertible preferred stock | - | - | - | (372) | |||||||||||||||
Series A & B convertible preferred stock - beneficial conversion feature | - | - | - | (9,399) | |||||||||||||||
Net loss attributable to common stockholders | $ | (9,526) | $ | (6,516) | $ | (18,660) | $ | (23,821) | |||||||||||
Net loss per share | |||||||||||||||||||
Basic & diluted | $ | (0.12) | $ | (0.12) | $ | (0.24) | $ | (0.57) | |||||||||||
Weighted average common shares outstanding | |||||||||||||||||||
Basic & diluted | 76,389,525 | 52,442,597 | 76,384,077 | 42,037,405 | |||||||||||||||
Leap Therapeutics, Inc. | ||||||||||
Consolidated Balance Sheets | ||||||||||
(in thousands, except share and per share amounts) | ||||||||||
June 30, | December 31, | |||||||||
2021 | 2020 | |||||||||
(Unaudited) | ||||||||||
Assets | ||||||||||
Current assets: | ||||||||||
Cash and cash equivalents | $ 35,734 | $ 52,071 | ||||||||
Research and development incentive receivable | 22 | 73 | ||||||||
Prepaid expenses and other current assets | 264 | 130 | ||||||||
Total current assets | 36,020 | 52,274 | ||||||||
Property and equipment, net | 50 | 65 | ||||||||
Property and equipment, net | 337 | 528 | ||||||||
Research and development incentive receivable, net of current portion | 309 | - | ||||||||
Deferred tax assets | 176 | 179 | ||||||||
Deferred costs | 68 | 345 | ||||||||
Deposits | 980 | 980 | ||||||||
Total assets | $ 37,940 | $ 54,371 | ||||||||
Liabilities and Stockholders' Equity | ||||||||||
Current liabilities: | ||||||||||
Accounts payable | $ 4,343 | $ 2,717 | ||||||||
Accrued expenses | 2,609 | 2,747 | ||||||||
Deferred revenue | 750 | 1,500 | ||||||||
Lease liability - current portion | 354 | 408 | ||||||||
Total current liabilities | 8,056 | 7,372 | ||||||||
Non current liabilities: | ||||||||||
Restricted stock liability | - | 204 | ||||||||
Lease liability, net of current portion | - | 144 | ||||||||
Total liabilities | 8,056 | 7,720 | ||||||||
Stockholders' equity: | ||||||||||
Common stock, | 60 | 60 | ||||||||
Additional paid-in capital | 271,918 | 270,155 | ||||||||
Accumulated other comprehensive loss | (449) | (579) | ||||||||
Accumulated deficit | (241,645) | (222,985) | ||||||||
Total stockholders' equity | 29,884 | 46,651 | ||||||||
Total liabilities and stockholders' equity | $ 37,940 | $ 54,371 | ||||||||
Leap Therapeutics, Inc. | |||||||||||||
Condensed Consolidated Statements of Cash Flows | |||||||||||||
(in thousands) | |||||||||||||
(Unaudited) | |||||||||||||
Six Months Ended June 30 | |||||||||||||
2021 | 2020 | ||||||||||||
Cash used in operating activities | $ | (16,339) | $ | (13,377) | |||||||||
Cash provided by investing activities | - | 25 | |||||||||||
Cash provided by financing activities | 18 | 74,382 | |||||||||||
Effect of exchange rate changes on cash and cash equivalents | (16) | (34) | |||||||||||
Net increase (decrease) in cash and cash equivalents | (16,337) | 60,996 | |||||||||||
Cash and cash equivalents at beginning of period | 52,071 | 3,891 | |||||||||||
Cash and cash equivalents at end of period | $ | 35,734 | $ | 64,887 | |||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-reports-second-quarter-2021-financial-results-and-upcoming-data-presentation-301354883.html
SOURCE Leap Therapeutics, Inc.
FAQ
What were Leap Therapeutics' net losses for Q2 2021?
How did research and development expenses change in Q2 2021 for LPTX?
When will LPTX present data from the DisTinGuish study?
What are the financial results for Leap Therapeutics in Q2 2021?
How much cash does Leap Therapeutics have as of June 30, 2021?
